Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:PolyC12U in the treatment of HIV infection

Overview of attention for article published in European Journal of Clinical Microbiology & Infectious Diseases, July 1996

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#35 of 4,225)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 10 news outlets

patent: 1 patent

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 11 news stories from 10 outlets.

AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

JCN Newswire, 18 Feb 2020

OCALA, FL / ACCESSWIRE, Feb, 18 2020 - (ACN Newswire) - AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused…

AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

DMN Newswire!, 18 Feb 2020

– (ACN Newswire) – AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on the research and development of…

AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

Biz Wire Express, 18 Feb 2020

- (ACN Newswire) - AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on the research and development of…

AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

Quamnet, 18 Feb 2020

- (ACN Newswire) - AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on the research and development of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 7 additional news stories.